These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Achieving cholesterol goals. Current and future drug therapies.
    Author: Jones PH.
    Journal: Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635.
    Abstract:
    Low-density lipoprotein cholesterol (LDL-C), the prime target of antilipidemic therapy, should be lowered to below 100 mg/dL for patients with coronary heart disease (CHD) and CHD risk equivalents, including diabetes, noncoronary atherosclerotic disorders, and multiple risk factors and a 10-year CHD risk greater than 20%. Five 3-hydroxy-3- methylglutaryl-CoenzymeA reductase inhibitors ("statins") are approved for use in the United States. A sixth, rosuvastatin, is awaiting approval. Of all the statins, rosuvastatin provides the greatest reductions in LDL-C along with the greatest increases in high-density lipoprotein cholesterol. The statins can be used alone, or in combination with a bile acid sequestrant, ezetimibe, or niacin in patients with mixed dyslipidemias.
    [Abstract] [Full Text] [Related] [New Search]